- Home
- DJCO vs ACRS Comparison
DJCO vs ACRS Comparison
Compare DJCO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | ACRS |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.0M | 868.5M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DJCO | ACRS |
|---|---|---|
| Price | $608.74 | $5.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 41.3K | ★ 1.8M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.50 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,384,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $348.63 | $1.74 |
| 52 Week High | $674.75 | $6.52 |
Technical Indicators
Market Signals| Indicator | DJCO | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 53.62 |
| Support Level | $554.92 | $4.13 |
| Resistance Level | $618.27 | $5.87 |
| Average True Range (ATR) | 28.45 | 0.35 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 85.30 | 48.84 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.